TrialCancer medicine2024

Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study.

Zhimin Shao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.